[6-K] Can-Fite BioPharma Ltd. Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. (CANF) submitted a Form 6-K to furnish a new press release about its liver cancer drug candidate Namodenoson. The filing states that the first paragraph of the press release is incorporated by reference into several existing Form S-8 and Form F-3 registration statements, meaning that key descriptive information about the company and its programs is now formally part of those documents. The press release, titled “Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson,” highlights an advanced liver cancer patient who achieved 9-year survival with a complete cure while being treated with Namodenoson. The Form 6-K itself does not provide additional clinical data or financial details beyond announcing and cross-referencing this communication.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of November 2025

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

The first paragraph of the press release attached hereto as Exhibit 99.1 is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384 and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On November 18, 2025, Can-Fite BioPharma Ltd. issued a press release entitled “Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson”. A copy of this press release is furnished herewith as Exhibit 99.1.

1

Exhibit Index

Exhibit No.		Description
99.1		Press Release dated November 18, 2025

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 18, 2025	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

3

FAQ

What did Can-Fite BioPharma Ltd. (CANF) announce in this Form 6-K?

Can-Fite BioPharma Ltd. reported that it issued a press release titled “Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson,” and furnished that press release as an exhibit.

How is the new press release used in Can-Fite (CANF) registration statements?

The filing states that the first paragraph of the press release attached as Exhibit 99.1 is incorporated by reference into Can-Fite’s existing Form S-8 and Form F-3 registration statements, becoming part of those documents from the submission date unless later superseded.

Which forms are affected by the incorporation by reference for Can-Fite (CANF)?

The first paragraph of the press release is incorporated into Form S-8 registration statements with File Nos. 333-227753, 333-271384 and 333-278525, and Form F-3 registration statements with File Nos. 333-236064, 333-274316, 333-262055, 333-276000 and 333-281872.

What medical result does the Can-Fite press release headline highlight?

The press release headline highlights a 9-year survival with complete cure in an advanced liver cancer patient who was treated with Namodenoson.

Does this Can-Fite Form 6-K include financial or earnings data?

No. The Form 6-K focuses on furnishing the press release and incorporating its first paragraph into specified registration statements; it does not present financial or earnings data.

Who signed the Can-Fite (CANF) Form 6-K report?

The report was signed by Motti Farbstein, who is identified as Chief Executive Officer and Chief Financial Officer of Can-Fite BioPharma Ltd.